Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis.

Bonello F, Pulini S, Ballanti S, Gentile M, Spada S, Annibali O, Omedé P, Ronconi S, Cangialosi C, Podda L, Palmas A, Malfitano A, Rivoli G, Belotti A, Ciambelli F, Vincelli ID, Cafro AM, Innao V, Palumbo A, Sonneveld P, Spencer A, Hájek R, Boccadoro M, Gay F.

Cancers (Basel). 2019 Nov 5;11(11). pii: E1735. doi: 10.3390/cancers11111735.

2.

Sensitivity of cutaneous chronic myelomonocytic leukaemia lesions to hypomethylating treatment.

Di Battista V, Matteucci C, Pulini S, Calabrese G, Quintini M, Moretti M, Ballanti S, Canino S, Di Bartolomeo P, Mecucci C.

Eur J Dermatol. 2017 Oct 1;27(5):540-542. doi: 10.1684/ejd.2017.3068. No abstract available.

PMID:
29084640
3.

Familial acquired thrombotic thrombocytopenic purpura: immunogenetic link with HLA-DRB1*11 and DQB1*03 antigens.

Lombardi AM, Pulini S, Passeri C, Iuliani O, Salutari P, Businaro A, Fabris F, Vianello F.

Br J Haematol. 2018 Oct;183(2):317-319. doi: 10.1111/bjh.14975. Epub 2017 Oct 26. No abstract available.

PMID:
29076136
4.

Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma.

Offidani M, Corvatta L, Liberati AM, Pulini S, Ballanti S, Bringhen S.

Leuk Lymphoma. 2018 May;59(5):1271-1273. doi: 10.1080/10428194.2017.1372575. Epub 2017 Sep 11. No abstract available.

PMID:
28891359
5.

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.

Magarotto V, Bringhen S, Offidani M, Benevolo G, Patriarca F, Mina R, Falcone AP, De Paoli L, Pietrantuono G, Gentili S, Musolino C, Giuliani N, Bernardini A, Conticello C, Pulini S, Ciccone G, Maisnar V, Ruggeri M, Zambello R, Guglielmelli T, Ledda A, Liberati AM, Montefusco V, Hajek R, Boccadoro M, Palumbo A.

Blood. 2016 Mar 3;127(9):1102-8. doi: 10.1182/blood-2015-08-662627. Epub 2016 Jan 4. Erratum in: Blood. 2018 Mar 29;131(13):1495.

6.

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.

Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L, Carella A, Malfitano A, Petrò D, Evangelista A, Spada S, Pescosta N, Omedè P, Campbell P, Liberati AM, Offidani M, Ria R, Pulini S, Patriarca F, Hajek R, Spencer A, Boccadoro M, Palumbo A.

Lancet Oncol. 2015 Dec;16(16):1617-29. doi: 10.1016/S1470-2045(15)00389-7. Epub 2015 Nov 17.

7.

Visceral leishmaniasis in relapsed and overtreated multiple myeloma in the era of high dose and "novel agent" therapy.

Torti L, Pulini S, Morelli AM, Bacci F, Di Bartolomeo P.

Int J Hematol. 2015 Oct;102(4):391-3. doi: 10.1007/s12185-015-1863-4. Epub 2015 Sep 10. No abstract available.

PMID:
26358056
8.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG.

Lancet Oncol. 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6.

PMID:
25242045
9.

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.

Offidani M, Corvatta L, Maracci L, Liberati AM, Ballanti S, Attolico I, Caraffa P, Alesiani F, Caravita di Toritto T, Gentili S, Tosi P, Brunori M, Derudas D, Ledda A, Gozzetti A, Cellini C, Malerba L, Mele A, Andriani A, Galimberti S, Mondello P, Pulini S, Coppetelli U, Fraticelli P, Olivieri A, Leoni P.

Blood Cancer J. 2013 Nov 22;3:e162. doi: 10.1038/bcj.2013.58.

10.

[Working overseas and cardiovascular diseases: application of a screening method on Oil&Gas employees].

Cappelli MI, Macchione M, Pulini S, Aquilina T, Cancanelli G.

G Ital Med Lav Ergon. 2012 Jul-Sep;34(3 Suppl):643-5. Italian.

PMID:
23405740
11.

Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.

Offidani M, Polloni C, Cavallo F, Liberati AM, Ballanti S, Pulini S, Catarini M, Alesiani F, Corvatta L, Gentili S, Caraffa P, Boccadoro M, Leoni P, Palumbo A.

Leuk Lymphoma. 2012 Sep;53(9):1722-7. doi: 10.3109/10428194.2012.664844. Epub 2012 Mar 16.

PMID:
22335534
12.

Paroxysmal nocturnal hemoglobinuria after autologous stem cell transplantation: extinction of the clone during treatment with eculizumab - pathophysiological implications of a unique clinical case.

Pulini S, Marando L, Natale A, Pascariello C, Catinella V, Del Vecchio L, Risitano AM, Fioritoni G.

Acta Haematol. 2011;126(2):103-9. doi: 10.1159/000327251. Epub 2011 May 19.

PMID:
21597283
13.

Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.

Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M, Nozzoli C, Ria R, Marasca R, Montefusco V, Baldini L, Elice F, Callea V, Pulini S, Carella AM, Zambello R, Benevolo G, Magarotto V, Tacchetti P, Pescosta N, Cellini C, Polloni C, Evangelista A, Caravita T, Morabito F, Offidani M, Tosi P, Boccadoro M.

J Clin Oncol. 2011 Mar 10;29(8):986-93. doi: 10.1200/JCO.2010.31.6844. Epub 2011 Jan 31.

PMID:
21282540
14.

Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials.

Offidani M, Leoni P, Corvatta L, Polloni C, Gentili S, Liberati AM, Pulini S, Gozzetti A, Ballanti S, Nozzoli C, Palumbo A.

Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):353-60. doi: 10.3816/CLML.2010.n.068. Review.

PMID:
21030348
15.

Lesional skin chemokine CTACK/CCL27 expression in mycosis fungoides and disease control by IFN-alpha and PUVA therapy.

Goteri G, Rupoli S, Campanati A, Costagliola A, Sabato S, Stramazzotti D, Picardi P, Canafoglia L, Pulini S, Ganzetti G, Offidani AM, Leoni P.

Am J Transl Res. 2009 Jan 31;1(2):203-10.

16.

Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies.

Pulini S, Rupoli S, Goteri G, Pimpinelli N, Alterini R, Bettacchi A, Mulattieri S, Picardi P, Tassetti A, Scortechini AR, Fioritoni G, Leoni P.

Eur J Haematol. 2009 Mar;82(3):184-93. doi: 10.1111/j.1600-0609.2008.01197.x.

PMID:
19215609
17.

Prognostic markers in mycosis fungoides.

Goteri G, Rupoli S, Pulini S, Tassetti A, Leoni P.

Anal Quant Cytol Histol. 2008 Aug;30(4):187-9. No abstract available.

PMID:
18773735
18.

[Occupational stress and job insecurity in men working in a university].

Di Donato A, Di Giampaolo L, Forcella L, Grapshi M, D'Intino A, Pulini S, Di Giuseppe D, Tamellini L, Qin-Li Z, Turano A, Di Camillo C, Boscolo P.

G Ital Med Lav Ergon. 2007 Jul-Sep;29(3 Suppl):808-10. Italian.

PMID:
18409973
19.

[Anxiety, job stress and job insecurity among teachers with indefinite or definite time contract].

Forcella L, Di Donato A, Coccia U, Tamellini L, Di Giampaolo L, Grapsi M, D'Intino A, Pulini S, Di Giuseppe D, Turano A, Boscolo P.

G Ital Med Lav Ergon. 2007 Jul-Sep;29(3 Suppl):683-6. Italian.

PMID:
18409903
20.

[Technical survey of safety levels established in building sites in the Pescara area].

Antonucci A, Pacini A, Siciliano E, Grapshi M, Pulini S, Boscolo P, Di Giampaolo L.

G Ital Med Lav Ergon. 2007 Jul-Sep;29(3 Suppl):637-8. Italian.

PMID:
18409880
21.

Coexistence of two discordant B-cell lymphomas in the skin and lymph node: report of a case with primary cutaneous follicle-center lymphoma and nodal mantle-cell lymphoma.

Goteri G, Rupoli S, Stramazzotti D, Discepoli G, Scortechini AR, Giacchetti A, Morichetti D, Tassetti A, Pulini S, Mulattieri S, Stronati A, Leoni P.

Br J Dermatol. 2007 Sep;157(3):629-31. Epub 2007 Jun 26. No abstract available.

PMID:
17596170
22.

Portal venous thrombosis in a young patient with idiopathic myelofibrosis and intrahepatic extramedullary hematopoiesis: a difficult diagnosis, prognosis and management.

Pulini S, D'Amico E, Basilico R, Mereu M, Bacci F, Spadano A, Fioritoni G.

Leukemia. 2007 Nov;21(11):2373-5. Epub 2007 Jun 21. No abstract available.

PMID:
17581614
23.

Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas.

Pulini S, Rupoli S, Goteri G, Pimpinelli N, Alterini R, Tassetti A, Scortechini AR, Offidani M, Mulattieri S, Stronati A, Brandozzi G, Giacchetti A, Mozzicafreddo G, Ricotti G, Filosa G, Bettacchi A, Simonacci M, Novelli N, Leoni P.

Haematologica. 2007 May;92(5):686-9.

24.

Severe diarrhoea during Campath-1H treatment for refractory cutaneous T-cell lymphoma.

Goteri G, Rupoli S, Tassetti A, Pulini S, Morichetti D, Filosa A, Mandolesi A, Veccia S, Leoni P, Bearzi I.

Ann Hematol. 2006 Sep;85(9):617-9. Epub 2006 Jul 4. No abstract available.

PMID:
16821018
25.

Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides.

Rupoli S, Goteri G, Pulini S, Filosa A, Tassetti A, Offidani M, Filosa G, Mozzicafreddo G, Giacchetti A, Brandozzi G, Cataldi I, Barulli S, Ranaldi R, Scortechini AR, Capretti R, Fabris G, Leoni P; Marche Regional Multicentric Study Group of Cutaneous Lymphomas.

Eur J Haematol. 2005 Aug;75(2):136-45.

PMID:
16000130
26.

Carboplatin and gemcitabine in the palliative treatment of stage IV non-small cell lung cancer: definitive results of a phase II trial.

Tassinari D, Fochessati F, Arcangeli V, Sartori S, Agostini V, Fantini M, Genestreti G, Grassia S, Ioli G, Imola M, Iorio D, Mianulli AM, Monticelli G, Oliverio G, Panzini I, Papi M, Poggi B, Polselli A, Pulini S, Tamburini E, Fattori PP, Ravaioli A.

Tumori. 2004 Jan-Feb;90(1):54-9.

PMID:
15143973

Supplemental Content

Loading ...
Support Center